SCHEMBL6856846

SCHEMBL6856846

CN(c1cc(N2CCCNCC2)ccc1NS(=O)(=O)c1ccccc1)S(C)(=O)=O

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 17/20 0.53
LMNA P02545 1/20 0.44
KAT6A Q92794 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3622887 0.99 HTR6 (0.53) HTR6LMNAKAT6A
SCHEMBL3622339 0.92 HTR6 (0.55) HTR6LMNAKAT6A
Hydrochloric Acid SCHEMBL3622014 0.91 HTR6 (0.54) HTR6LMNAKAT6A
SCHEMBL3623801 0.91 MAPT (0.47) HTR6LMNA
Hydrochloric Acid SCHEMBL3623155 0.90 MAPT (0.46) HTR6
Hydrochloric Acid SCHEMBL3625041 0.89 RAD52 (0.53) HTR6
SCHEMBL3625209 0.85 HTR6 (0.48) HTR6
Hydrochloric Acid SCHEMBL3617005 0.84 HTR6 (0.47) HTR6
SCHEMBL3622751 0.84 HTR6 (0.63) HTR6LMNAKAT6A
SCHEMBL3616826 0.83 HTR6 (0.50) HTR6LMNAKAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406884-A1 ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS BIOVITRUM AB (SE) 2004-04-14 EP disclosed
WO-2002092585-A1 NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS BIOVITRUM AB (SE) 2002-11-21 WO disclosed